Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Form 8.5 - NetScientific PLC

4 Jan 2019 09:13

RNS Number : 2240M
W.H. Ireland Limited
04 January 2019
 

FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

WH Ireland Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

NetScientific PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

NetScientific PLC

(d) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

03/01/2019

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

No

 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

NetScientific PLC 5p Ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

6776

0.00

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

TOTAL:

6776

 

0.00

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

Ordinary 5p

 

Sales

 

 

 

 

186

 

 

 

7.5p

 

 

 

7.5p

 

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

04/01/2019

 

Contact name:

Christopher Houghton

 

Telephone number:

0161 819 8866

 

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FEOUGUUGGUPBUBC
Date   Source Headline
18th Feb 20194:54 pmRNSHolding(s) in Company
18th Feb 201911:06 amRNSSecond Price Monitoring Extn
18th Feb 201911:00 amRNSPrice Monitoring Extension
15th Feb 201912:00 pmRNSConclusion of Strategic Review
14th Feb 201912:07 pmRNSGlycotest Receives First $3m Tranche from Fosun
15th Jan 201911:08 amRNSTermination of Formal Sales Process
15th Jan 20199:37 amRNSForm 8.5 - NetScientific plc
14th Jan 201910:25 amRNSForm 8.5 - NetScientific PLC
8th Jan 201911:58 amRNSForm 8.5 - NetScientific PLC
7th Jan 201910:14 amRNSForm 8.5 - NetScientific PLC
4th Jan 20199:13 amRNSForm 8.5 - NetScientific PLC
31st Dec 20189:36 amRNSForm 8.5 - NetScientific PLC
24th Dec 201810:23 amRNSForm 8.5 - NetScientific PLC
21st Dec 201811:04 amRNSForm 8.5 - NetScientific PLC
20th Dec 20184:41 pmRNSSecond Price Monitoring Extn
20th Dec 20184:36 pmRNSPrice Monitoring Extension
20th Dec 201810:28 amRNSForm 8.5 - NetScientific PLC
20th Dec 20187:00 amRNSUpdate on Strategic Review
19th Dec 201811:03 amRNSForm 8.3 - NetScientific Plc
19th Dec 201811:00 amRNSForm 8.3 - NetScientific plc
19th Dec 20189:34 amRNSForm 8.5 - NetScientific PLC
18th Dec 20189:32 amRNSForm 8.5 - NetScientific PLC
13th Dec 20189:06 amRNSForm 8.5 - NetScientific PLC
7th Dec 201810:23 amRNSForm 8.5 - NetScientific PLC
5th Dec 20189:14 amRNSForm 8.5 - NetScientific PLC
4th Dec 20189:50 amRNSForm 8.5 - NetScientific PLC
3rd Dec 201810:31 amRNSForm 8.5 - NetScientific PLC
30th Nov 20183:46 pmRNSForm 8 (OPD) - NetScientific (Offeree)
30th Nov 201811:35 amRNSForm 8.5 - NetScientific PLC
29th Nov 20181:29 pmRNSForm 8.3 - NetScientific Plc
29th Nov 201812:49 pmRNSForm 8.3 - NetScientific Plc
29th Nov 201810:26 amRNSForm 8.5 - NetScientific PLC
28th Nov 20181:46 pmRNSForm 8.3 - NetScientific Plc
28th Nov 20189:51 amRNSForm 8.5 - NetScientific PLC
27th Nov 201812:44 pmGNWInvesco Ltd.: Form 8.3 - Netscientific Plc
27th Nov 201812:34 pmRNSForm 8.3 - NetScientfic Plc
27th Nov 201810:33 amRNSForm 8.5 - NetScientific PLC
27th Nov 20189:36 amRNSForm 8.3 - NetScientific PLC
26th Nov 20183:01 pmRNSAmendment to Executive Director Service Terms
26th Nov 20183:00 pmRNSAnnouncement of Strategic Review
26th Nov 201812:30 pmRNSPDS Announces Merger with Edge Therapeutics
8th Nov 20187:00 amRNSVortex Improves CTC Enumeration with Impedance
1st Nov 20187:00 amRNSVortex and STRATEC Announce Global Partnership
22nd Oct 20181:01 pmRNSGlycotest Completes $10m Series A Round with Fosun
22nd Oct 20187:00 amRNSGlycotest Completes $10m Series A Round with Fosun
28th Sep 20187:00 amRNSInterim Results
20th Sep 20187:00 amRNSProAxsis Immunoassays Selected for Large Trial
15th Aug 20187:00 amRNSWanda Launches CareLink, New Digital Health App
2nd Aug 20187:02 amRNSProAxsis Granted Third Respiratory Field CE Mark
2nd Aug 20187:00 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.